PHP Code

Using the PHP code extracts allows Academic Staff Profiles to be displayed in a number of different styles including the tabbed format shown below - the data is provided dynamically from the IRIS application, while maintaning the consistent look and feel of your site.

Prof William Rosenberg

  • Telephone:

    0207 794 0500

  • Extension:

    #6 29294 0500

  • Email:

    w.rosenberg@ucl.ac.uk

  • Address:

    LG631 Royal Free Hospital,
    Pond Street,
    London,
    NW3 2QG

  • Appointments:

    Peter Scheuer Chair of Liver Disease, lnstitute of Liver and Digestive Health, Div of Medicine
No image is available

Research Summary

The Group has a long-standing interest in the immune response to hepatitis viruses. We have built upon knowledge of the interactions between host and viruses to develop vaccines for the prophylaxis and treatment of viral hepatitis. In addition we investigate biomarkers of liver fibrosis. Our work has led to the identification of a panel of markers that can determine the severity of liver fibrosis and prognosis. We are currently undertaking further research to identify new markers of liver fibrosis using metabonomics and proteomics. The Group also initiates and participates in clinical studies ranging from epidemiology to clinical trials of drugs and diagnostic tests.

Research Activities

  • Clinical trials
  • Hepatology
  • Immunopathogenesis of hepatitis B virus infection

Recent Publications

Displaying 50 most recent publications. For the full list please visit UCL Discovery

  1. Tanwar S,Trembling PM,Guha IN,Parkes J,Kaye P,Burt AD,Ryder SD,Aithal GP,Day CP,Rosenberg WM (2013) Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. Hepatology, 57(1), 103 - 111. 10.1002/hep.26030.
  2. Abignano G,Cuomo G,Buch MH,Rosenberg WM,Valentini G,Emery P,Del Galdo F (2013) The enhanced liver fibrosis test: a clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis. Ann Rheum Dis. 10.1136/annrheumdis-2012-202843.
  3. Schurich A,Pallett LJ,Lubowiecki M,Singh HD,Gill US,Kennedy PT,Nastouli E,Tanwar S,Rosenberg W,Maini MK (2013) The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells. PLoS Pathog, 9(3), e1003208. 10.1371/journal.ppat.1003208.
  4. Rodger AJ,Tedder RS,Fries L,Ijaz S (2012) The diversity and management of chronic hepatitis B virus infections in the UK – A wake up call Clinical Infectious Diseases.
  5. Tanwar S,Trembling PM,Hogan BJ,Thorburn D,Guha IN,Parkes J,Kaye P,Burt AD,Ryder SD,Aithal GP,Day CP,Rosenberg WM (2012) An algorithm combining direct and indirect liver fibrosis tests enhances diagnostic performance for the detection of advanced fibrosis (F3-4) in NAFLD minimising the need for liver biopsy HEPATOLOGY, 56, 264A - 264A.
  6. Ingegnoli F,Gualtierotti R,Schioppo T,Orenti A,Boracchi P,Lubatti C,Rizzini SL,Murgo A,Zeni S,Mastaglio C,Galbiati V,Grossi C,Borghi M,Rosenberg WM,Meroni PL (2012) Enhanced Liver Fibrosis Test: A Further Step Toward Depiction of Fibrotic Process in Very Early Diagnosis of Systemic Sclerosis ARTHRITIS AND RHEUMATISM, 64(10), S632 - S632.
  7. Khan SA,Davidson BR,Goldin RD,Heaton N,Karani J,Pereira SP,Rosenberg WMC,Tait P,Taylor-Robinson SD,Thillainayagam AV,Thomas HC,Wasan H (2012) Guidelines for the diagnosis and treatment of cholangiocarcinoma: An update Gut, 61(12), 1657 - 1669.
  8. Deuffic-Burban S,Deltenre P,Buti M,Stroffolini T,Parkes J,Mühlberger N,Siebert U,Moreno C,Hatzakis A,Rosenberg W,Zeuzem S,Mathurin P (2012) Predicted effects of treatment for HCV infection vary among European countries Gastroenterology, 143(4), 974 - 985.e13.
  9. Khan SA,Davidson BR,Goldin RD,Heaton N,Karani J,Pereira SP,Rosenberg WM,Tait P,Taylor-Robinson SD,Thillainayagam AV,Thomas HC,Wasan H,British Society of Gastroenterology (2012) Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut, 61(12), 1657 - 1669. 10.1136/gutjnl-2011-301748.
  10. Trembling PM,Parkes J,Tanwar S,Burt AD,Rosenberg WM,Investigators ELF (2012) ENHANCED LIVER FIBROSIS TEST ACCURATELY IDENTIFIES LIVER FIBROSIS AND PREDICTS CLINICAL OUTCOMES IN ALCOHOLIC LIVER DISEASE JOURNAL OF HEPATOLOGY, 56, S424 - S424.
  11. Tanwar S,Trembling PM,Ellis E,Parkes J,Herold C,Schuppan D,Rosenberg WM (2012) DIRECT NON-INVASIVE SERUM MARKERS OF LIVER FIBROSIS PREDICT FIBROSIS EVOLUTION IN CHRONIC HEPATITIS C BUT ARE INCREASED BY INTERFERON-BASED THERAPY JOURNAL OF HEPATOLOGY, 56, S423 - S423.
  12. Tanwar S,Trembling PM,Thorburn D,Guha IN,Parkes J,Kaye P,Burt A,Ryder SD,Aithal G,Day C,Rosenberg WM (2012) DIRECT SERUM MARKERS ARE MORE ACCURATE THAN SIMPLE MARKER PANELS FOR THE DETECTION OF FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) GUT, 61, A414 - A414. 10.1136/gutjnl-2012-302514d.286.
  13. Tanwar S,Trembling PM,Ellis E,Parkes J,Herold C,Schuppan D,Rosenberg WMC (2012) DIRECT NON-INVASIVE SERUM MARKERS OF LIVER FIBROSIS PREDICT FIBROSIS EVOLUTION IN CHRONIC HEPATITIS C BUT ARE INCREASED BY INTERFERON-BASED THERAPY GUT, 61, A143 - A144. 10.1136/gutjnl-2012-302514b.172.
  14. Trembling PM,Cheung M,Tanwar S,Rosenberg WM (2012) CONCORDANCE OF NON-INVASIVE MARKERS OF LIVER FIBROSIS IN A MIXED POPULATION OF LIVER DISEASES GUT, 61, A408 - A408. 10.1136/gutjnl-2012-302514d.272.
  15. Schurich A,Pallett LJ,Lubowiecki M,Singh HD,Rosenberg W,Maini MK (2012) The third signal cytokine IL-12 rescues anti-viral responses in exhausted CD8 T cells IMMUNOLOGY, 137, 115 - 115.
  16. Hogan B,Trembling PM,Tanwar S,Yu D,O'Beirne JP,Rosenberg WM (2012) DO ALL REGENERATIVE NODULES BECOME HEPATOCELLULAR CARCINOMA? THE OUTCOME OF 4 YEARS MRI SURVEILLANCE GUT, 61, A192 - A192. 10.1136/gutjnl-2012-302514c.21.
  17. Trembling PM,Parkes J,Tanwar S,Burt AD,Rosenberg WM (2012) ENHANCED LIVER FIBROSIS TEST ACCURATELY IDENTIFIES LIVER FIBROSIS AND PREDICTS CLINICAL OUTCOMES IN ALCOHOLIC LIVER DISEASE GUT, 61, A408 - A409. 10.1136/gutjnl-2012-302514d.273.
  18. Nebbia G,Peppa D,Schurich A,Khanna P,Singh HD,Cheng Y,Rosenberg W,Dusheiko G,Gilson R,ChinAleong J,Kennedy P,Maini MK (2012) Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection. PLoS One, 7(10), e47648. 10.1371/journal.pone.0047648.
  19. Abignano G,Cuomo G,Buch MH,Rosenberg WM,Valentini G,Emery P,Del Galdo F (2012) ELF SCORE: A VALIDATED SERUM TEST STRONGLY PREDICTIVE OF FIBROSIS IN SYSTEMIC SCLEROSIS RHEUMATOLOGY, 51, 84 - 84.
  20. Hogan BJ,Trembling PM,Tanwar S,Yu D,O'Beirne JP,Rosenberg WM (2012) DO ALL ARTERIALISED NODULES BECOME HEPATOCELLULAR CARCINOMA? THE OUTCOME OF 4 YEARS MAGNETIC RESONANCE IMAGING SURVEILLANCE JOURNAL OF HEPATOLOGY, 56, S282 - S282.
  21. Tanwar S,Trembling PM,Thorburn D,Guha IN,Parkes J,Kaye P,Burt A,Ryder SD,Aithal G,Day C,Rosenberg WM (2012) DIRECT SERUM MARKERS ARE MORE ACCURATE THAN SIMPLE MARKER PANELS FOR THE DETECTION OF FIBROSIS IN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) JOURNAL OF HEPATOLOGY, 56, S423 - S423.
  22. Sackett DL,Rosenberg WM,Gray JA,Haynes RB,Richardson WS (2012) [What is EBM and what is not?]. Neuere Med Wiss Quellen Stud, 22, 13 - 17.
  23. Abignano G,Cuomo G,Buch M,Rosenberg WM,Valentini G,Emery P,Del Galdo F (2012) ELF SCORE: A VALIDATED SERUM TEST STRONGLY PREDICTIVE OF FIBROSIS IN SSc RHEUMATOLOGY, 51, 14 - 14.
  24. Tanwar S,Wright M,Foster GR,Ryder SD,Mills PR,Cramp ME,Parkes J,Rosenberg WM (2012) Randomized clinical trial: A pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis European Journal of Gastroenterology and Hepatology, 24(5), 543 - 550.
  25. Tanwar S,Wright M,Foster GR,Ryder SD,Mills PR,Cramp ME,Parkes J,Rosenberg WM (2012) Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis. Eur J Gastroenterol Hepatol, 24(5), 543 - 550. 10.1097/MEG.0b013e3283513e69.
  26. Parkes J,Guha IN,Harris S,Rosenberg WM,Roderick PJ (2012) Systematic review of the diagnostic performance of serum markers of liver fibrosis in alcoholic liver disease. Comp Hepatol, 11(1), 5. 10.1186/1476-5926-11-5.
  27. McLernon DJ,Dillon JF,Sullivan FM,Roderick P,Rosenberg WM,Ryder SD,Donnan PT (2012) The Utility of Liver Function Tests for Mortality Prediction within One Year in Primary Care Using the Algorithm for Liver Function Investigations (ALFI) PLoS ONE, 7(12).
  28. Wahl K,Rosenberg W,Vaske B,Manns MP,Schulze-Osthoff K,Bahr MJ,Bantel H (2012) Biopsy-Controlled Liver Fibrosis Staging Using the Enhanced Liver Fibrosis (ELF) Score Compared to Transient Elastography PLoS ONE, 7(12).
  29. Velazquez C,Macartney MJ,Irish DN,Tanwar S,Trembling PM,Hogan BJ,Catt J,Glasgow S,Winter L,Ju M,Moore MT,Hains M,Smith B,Suri D,Jacobs M,Oben JA,Nastouli E,Booth CL,Bridge S,Garcia-Diaz A,McCormick AL,Dusheiko G,Rosenberg WM,Haque T (2012) The impact of virologic resistance and adherence on treatment failure in a cohort of hepatitis C virus (HCV) infected patients treated with telaprevir (TVR) and boceprevir (BOC) HEPATOLOGY, 56, 716A - 717A.
  30. Ruth ND,Rosenberg WM,Sharif K,McKiernan PJ (2012) The predictive value of ELF test in patients with biliary atresia HEPATOLOGY, 56, 725A - 726A.
  31. Abignano G,Cuomo G,Buch MH,Rosenberg WM,Valentini G,Emery P,Del Galdo F (2012) Sub-Analysis of ELF Score Biomarkers Components Indicates a Specific Correlation with Different Organ Involvement in Systemic Sclerosis ARTHRITIS AND RHEUMATISM, 64(10), S632 - S633.
  32. Darbyshire J,Sitzia J,Cameron D,Ford G,Littlewood S,Kaplan R,Johnston D,Matthews D,Holloway J,Chaturvedi N,Morgan C,Riley A,Rossor M,Kotting P,McKeith I,Smye S,Gower J,Brown V,Smyth R,Poustie V,van't Hoff W,Wallace P,Ellis T,Wykes T,Burns S,Rosenberg W,Lester N,Stead M,Potts V,Johns C,Campbell H,Hamilton R,Sheffield J,Selby P (2011) Extending the clinical research network approach to all of healthcare. Ann Oncol, 22 Suppl 7, vii36 - vii43. 10.1093/annonc/mdr424.
  33. Barker J,Horn EJ,Lebwohl M,Warren RB,Nast A,Rosenberg W,Smith C,International Psoriasis Council (2011) Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. J Eur Acad Dermatol Venereol, 25(7), 758 - 764. 10.1111/j.1468-3083.2010.03932.x.
  34. Tanwar S,Ellis EL,Parkes J,Herold C,Rosenberg WM (2011) Changes in ELF Score During Treatment With Pegylated Interferon and Silymarin Are Associated With Progression of Histological Liver Disease in Non-Responder Patients With Chronic Hepatitis C GASTROENTEROLOGY, 140(5), S979 - S979.
  35. Deuffic-Burban S,Deltenre P,Buti M,Stroffolini T,Parkes J,Muehlberger N,Siebert U,Moreno C,Hatzakis A,Rosenberg W,Zeuzem S,Mathurin P (2011) HCV BURDEN IN EUROPE: IMPACT OF NATIONAL TREATMENT PRACTICES ON FUTURE HCV-RELATED MORBIDITY AND MORTALITY THROUGH A MODELING APPROACH JOURNAL OF HEPATOLOGY, 54, S54 - S54.
  36. Alkhouri N,Carter-Kent C,Lopez R,Rosenberg WM,Pinzani M,Bedogni G,Feldstein AE,Nobili V (2011) A Combination of the Pediatric NAFLD Fibrosis Index and Enhanced Liver Fibrosis Test Identifies Children With Fibrosis CLIN GASTROENTEROL H, 9(2), 150 - 155. 10.1016/j.cgh.2010.09.015.
  37. Stroffolini T,Deuffic-Burban S,Deltenre P,Buti M,Parkes J,Muehlberger N,Siebert U,Moreno C,Hatzakis A,Rosenberg W,Zeuzem S,Mathurin P (2011) HCV burden in Europe: Impact of national treatment practices on future HCV-related morbidity and mortality through a modeling approach DIGESTIVE AND LIVER DISEASE, 43, S70 - S70.
  38. Schurich A,Pallett L,Lubowiecki M,Singh H,Rosenberg W,Maini M (2011) Interleukin 12 mediated recovery of effector cytokine production in hepatitis B virus-specific CD8+T cells IMMUNOLOGY, 135, 58 - 58.
  39. Schurich A,Khanna P,Lubowiecki M,Lopes AR,Peppa D,Micco L,Nebbia G,Singh H,Rosenberg W,Kennedy PTF,Dusheiko G,Maini M (2011) ALTERING CO-INHIBITORY AND CO-STIMULATORY PATHWAYS TO RESTORE ANTI-VIRAL T CELL RESPONSES IN CHRONIC HBV INFECTION JOURNAL OF HEPATOLOGY, 54, S125 - S125.
  40. Nebbia G,Peppa D,Schurich A,Khanna P,Singh H,Rosenberg W,Dusheiko G,Gilson R,Chinaleong J,Kennedy P,Maini M (2011) Role of the TIM-3/Galectin-9 pathway in chronic hepatitis B infection IMMUNOLOGY, 135, 69 - 69.
  41. Peppa D,Gill U,Micco L,Schurich A,Nebbia G,Singh H,Rosenberg W,Gilson R,Kennedy PT,Maini M (2011) Susceptibility of T cells to death ligand-mediated deletion in the liver of chronic hepatitis B virus (CHB) infected patients IMMUNOLOGY, 135, 60 - 60.
  42. Abignano G,Cuomo G,Buch MH,Rosenberg WM,Valentini G,Emery P,Del Galdo F (2011) ELF Score: A Validated Serum Test Strongly Predictive of Fibrosis in Systemic Sclerosis. ARTHRITIS AND RHEUMATISM, 63(10), S273 - S273.
  43. Tanwar S,Trembling PM,Guha IN,Parkes J,Kaye P,Burt AD,Ryder SD,Aithal GP,Day CP,Rosenberg WM (2011) VALIDATION OF A NOVEL BIOMARKER MODEL FOR THE PREDICTION OF NON-ALCOHOLIC STEATOHEPATITIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE HEPATOLOGY, 54, 1123A - 1123A.
  44. Trépo E,Potthoff A,Pradat P,Bakshi R,Young B,Lagier R,Moreno C,Verset L,Cross R,Degré D,Lemmers A,Gustot T,Berthillon P,Rosenberg W,Trépo C,Sninsky J,Adler M,Wedemeyer H (2011) Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease. J Hepatol, 55(1), 38 - 44. 10.1016/j.jhep.2010.10.018.
  45. Fowell AJ,Collins JE,Duncombe DR,Pickering JA,Rosenberg WMC,Benyon RC (2011) Silencing tissue inhibitors of metalloproteinases (TIMPs) with short interfering RNA reveals a role for TIMP-1 in hepatic stellate cell proliferation BIOCHEM BIOPH RES CO, 407(2), 277 - 282. 10.1016/j.bbrc.2011.02.009.
  46. Tanwar S,Ellis E,Parkes J,Herold C,Rosenberg W (2011) CHANGES IN ELF SCORE DURING TREATMENT WITH PEGYLATED INTERFERON AND SILYMARIN ARE ASSOCIATED WITH PROGRESSION OF HISTOLOGICAL LIVER DISEASE IN NON-RESPONDER PATIENTS WITH CHRONIC HEPATITIS C GUT, 60. 10.1136/gut.2011.239301.527.
  47. Tanwar S,Ellis E,Parkes J,Herold C,Rosenberg W (2011) CHANGES IN ELF SCORE DURING TREATMENT WITH PEGYLATED INTERFERON AND SILYMARIN ARE ASSOCIATED WITH PROGRESSION OF HISTOLOGICAL LIVER DISEASE IN NON-RESPONDER PATIENTS WITH HEPATITIS C JOURNAL OF HEPATOLOGY, 54, S55 - S55.
  48. Peppa D,Micco L,Schurich A,Nebbia G,Khanna P,Singh H,Rosenberg W,Dusheiko G,Gilson R,Maini M (2011) FRATRICIDE OF HBV-SPECIFIC CD8 T CELLS BY NK CELLS MEDIATED THROUGH THE TRAIL PATHWAY JOURNAL OF HEPATOLOGY, 54, S40 - S41.
  49. Parkes J,Guha IN,Roderick P,Harris S,Cross R,Manos MM,Irving W,Zaitoun A,Wheatley M,Ryder S,Rosenberg W (2011) Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepat, 18(1), 23 - 31. 10.1111/j.1365-2893.2009.01263.x.
  50. Trembling PM,Lampertico P,Parkes J,Tanwar S,Vigano M,Facchetti F,Colombo M,Rosenberg WM (2011) COMPARISON OF ENHANCED LIVER FIBROSIS TEST AND TRANSIENT ELASTOGRAPHY FOR THE NON-INVASIVE ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HEPATITIS B HEPATOLOGY, 54, 1223A - 1223A.

Qualifications

  • 1992: Doctor of Philosophy, University of Oxford
  • 1992: Master of Arts, University of Oxford
  • 1987: Bachelor of Arts, University of Oxford
  • 1984: Master of Arts, University of Cambridge
  • 1983: Bachelor of Medicine/Bachelor of Surgery, University of London
  • 1980: Bachelor of Arts (Honours), University of Cambridge

Keywords

  • Biomarker
  • Epidemiology
  • Immune regulation
  • Immune response to hepatitis viruses
  • Infection
  • Infectious diseases
  • Inflammation
  • Liver immunology and toxicity
  • Viral hepatitis
  • Virology
  • biomarkers of liver fibrosis
  • vaccine development